Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
January 18, 2012Lara D. VeekenOpen Access

Development of resistance to biologic therapies with reference to IFN- 

View Full Paper
Ask AI
Bookmark
Share

Authors

RFRachel FarrellMMMónica MartaAGAdriana Gaeguta

Discussion

Loading...

Member takes

Overview

Key Points

Key points are not available for this paper at this time.

Cite This Study

Farrell et al. (2012) studied this question.

synapsesocial.com/papers/6a830bfdb2f729353b1f2523https://doi.org/10.1093/rheumatology/ker445
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Interferon beta‐1b inhibits gelatinase secretion and in vitro migration of human T cells: A possible mechanism for treatment efficacy in multiple sclerosis1996 · 298 citations
  2. 2Partial phenotypic correction and immune tolerance induction to enzyme replacement therapy after hematopoietic stem cell gene transfer of α‐glucosidase in Pompe disease2009 · 39 citations
  3. 3Severe infusion reactions to infliximab: aetiology, immunogenicity and risk factors in patients with inflammatory bowel disease2011 · 144 citations
  4. 4Serum IFN neutralizing antibodies and neopterin levels in a cross-section of MS patients2001 · 61 citations